These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15933616)

  • 1. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide and acute pancreatitis.
    Tripathy NR; Basha S; Jain R; Shetty S; Ramachandran A
    J Assoc Physicians India; 2008 Dec; 56():987-8. PubMed ID: 19322980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
    Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U
    Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535
    [No Abstract]   [Full Text] [Related]  

  • 4. Exenatide once weekly in type 2 diabetes.
    Scheen AJ
    Lancet; 2008 Oct; 372(9645):1197-8. PubMed ID: 18782642
    [No Abstract]   [Full Text] [Related]  

  • 5. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Exenatide (Byetta)].
    Duh D; Vandevijver A
    J Pharm Belg; 2008 Mar; 63(1):29-30. PubMed ID: 18479081
    [No Abstract]   [Full Text] [Related]  

  • 7. Byetta update: what we've learned from experience.
    Cornell S; Todd T
    Diabetes Self Manag; 2010; 27(2):28, 30-1. PubMed ID: 20405747
    [No Abstract]   [Full Text] [Related]  

  • 8. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes quiz. How much do you know about Byetta?
    Flannery L
    Diabetes Self Manag; 2007; 24(4):52, 54. PubMed ID: 17663084
    [No Abstract]   [Full Text] [Related]  

  • 10. Exenatide: excessive weight loss.
    Prescrire Int; 2011 Jan; 20(112):17. PubMed ID: 21462789
    [No Abstract]   [Full Text] [Related]  

  • 11. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 12. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.
    Kenny PR; Brady DE; Torres DM; Ragozzino L; Chalasani N; Harrison SA
    Am J Gastroenterol; 2010 Dec; 105(12):2707-9. PubMed ID: 21131943
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release exenatide (Bydureon) for type 2 diabetes.
    Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecule of the month. Exenatide.
    Drug News Perspect; 2003 Nov; 16(9):621. PubMed ID: 14702143
    [No Abstract]   [Full Text] [Related]  

  • 16. [Exenatide convinces in a six-month study: HbA1c sunk significantly].
    MMW Fortschr Med; 2009 May; 151(19):51. PubMed ID: 19827448
    [No Abstract]   [Full Text] [Related]  

  • 17. Beyond glycemic control: the role of incretin hormones.
    Ridge TD
    J Am Acad Nurse Pract; 2007; 19(11 Suppl 1):11-4. PubMed ID: 18341243
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
    Pawaskar MD; Blickensderfer AL; Hoogwerf BJ; Quimbo R; Wade R
    J Med Econ; 2011; 14(6):705-8. PubMed ID: 21892855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
    Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia.
    Cohen V; Teperikidis E; Jellinek SP; Rose J
    Clin Toxicol (Phila); 2008 Apr; 46(4):346-7. PubMed ID: 17852164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.